The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data to help researchers and drug developers understand what works, what doesn’t, and why. On Wednesday, January 24th, at 10:00 a.m. PT/1:00 p.m. ET, drug trial participant Bill Sasse was a participant in Eli Lilly’s clinical trial of experimental monoclonal antibody drug solanezumab. In March of 2023, solanezumab ultimately failed to hit its benchmarks in slowing cognitive decline and the trial was discontinued.
Sasse, whose father died of Alzheimer’s, had the unique experience of participating in a clinical trial for a MAB drug without having any symptoms of cognitive decline. An army veteran, retired business owner, grandparent, and a native of Columbus, Indiana, he joined the trial after being inspired by a documentary about Glen Campbell promoting the trial, asking himself, “Why not, me?”
With his wife as his trial partner, he participated in the solanezumab trial for eight years before it was announced that the clinical trial had failed. He has participated in panels with Eli Lilly on his experience with the trial.
RSVP to learn more about the clinical trial experience with MAB drugs.